These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
760 related articles for article (PubMed ID: 34688149)
1. The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19. Attiq A; Yao LJ; Afzal S; Khan MA Int Immunopharmacol; 2021 Dec; 101(Pt B):108255. PubMed ID: 34688149 [TBL] [Abstract][Full Text] [Related]
2. The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients. Hariharan A; Hakeem AR; Radhakrishnan S; Reddy MS; Rela M Inflammopharmacology; 2021 Feb; 29(1):91-100. PubMed ID: 33159646 [TBL] [Abstract][Full Text] [Related]
3. NF-κB Pathway as a Potential Target for Treatment of Critical Stage COVID-19 Patients. Kircheis R; Haasbach E; Lueftenegger D; Heyken WT; Ocker M; Planz O Front Immunol; 2020; 11():598444. PubMed ID: 33362782 [TBL] [Abstract][Full Text] [Related]
4. Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms. Sanghai N; Tranmer GK Drug Discov Today; 2020 Dec; 25(12):2076-2079. PubMed ID: 32949526 [TBL] [Abstract][Full Text] [Related]
5. Demystifying Excess Immune Response in COVID-19 to Reposition an Orphan Drug for Down-Regulation of NF-κB: A Systematic Review. Peddapalli A; Gehani M; Kalle AM; Peddapalli SR; Peter AE; Sharad S Viruses; 2021 Feb; 13(3):. PubMed ID: 33673529 [TBL] [Abstract][Full Text] [Related]
6. A Computational Approach Identified Andrographolide as a Potential Drug for Suppressing COVID-19-Induced Cytokine Storm. Rehan M; Ahmed F; Howladar SM; Refai MY; Baeissa HM; Zughaibi TA; Kedwa KM; Jamal MS Front Immunol; 2021; 12():648250. PubMed ID: 34248936 [TBL] [Abstract][Full Text] [Related]
7. Dehydrozingerone ameliorates Lipopolysaccharide induced acute respiratory distress syndrome by inhibiting cytokine storm, oxidative stress via modulating the MAPK/NF-κB pathway. Tirunavalli SK; Gourishetti K; Kotipalli RSS; Kuncha M; Kathirvel M; Kaur R; Jerald MK; Sistla R; Andugulapati SB Phytomedicine; 2021 Nov; 92():153729. PubMed ID: 34517257 [TBL] [Abstract][Full Text] [Related]
8. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19. Al-Kuraishy HM; Al-Gareeb AI; Mostafa-Hedeab G; Kasozi KI; Zirintunda G; Aslam A; Allahyani M; Welburn SC; Batiha GE Front Immunol; 2021; 12():749291. PubMed ID: 34867978 [TBL] [Abstract][Full Text] [Related]
9. Role of DAMPs in respiratory virus-induced acute respiratory distress syndrome-with a preliminary reference to SARS-CoV-2 pneumonia. Land WG Genes Immun; 2021 Jul; 22(3):141-160. PubMed ID: 34140652 [TBL] [Abstract][Full Text] [Related]
10. Predictions based on inflammatory cytokine profiling of Egyptian COVID-19 with 2 potential therapeutic effects of certain marine-derived compounds. Elnosary ME; Shreadah MA; Ashour ML; Nabil-Adam A Int Immunopharmacol; 2024 Jan; 126():111072. PubMed ID: 38006751 [TBL] [Abstract][Full Text] [Related]
11. Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone. Olajide OA; Iwuanyanwu VU; Lepiarz-Raba I; Al-Hindawi AA Inflammation; 2021 Oct; 44(5):1865-1877. PubMed ID: 33860869 [TBL] [Abstract][Full Text] [Related]
12. The Many Faces of JAKs and STATs Within the COVID-19 Storm. Grant AH; Estrada A; Ayala-Marin YM; Alvidrez-Camacho AY; Rodriguez G; Robles-Escajeda E; Cadena-Medina DA; Rodriguez AC; Kirken RA Front Immunol; 2021; 12():690477. PubMed ID: 34326843 [TBL] [Abstract][Full Text] [Related]
14. How do deer respiratory epithelial cells weather the initial storm of SARS-CoV-2 WA1/2020 strain? Sarlo Davila KM; Nelli RK; Phadke KS; Ruden RM; Sang Y; Bellaire BH; Gimenez-Lirola LG; Miller LC Microbiol Spectr; 2024 Feb; 12(2):e0252423. PubMed ID: 38189329 [TBL] [Abstract][Full Text] [Related]
15. NF-κB signalling as a pharmacological target in COVID-19: potential roles for IKKβ inhibitors. Kandasamy M Naunyn Schmiedebergs Arch Pharmacol; 2021 Mar; 394(3):561-567. PubMed ID: 33394134 [TBL] [Abstract][Full Text] [Related]
16. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy. Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027 [TBL] [Abstract][Full Text] [Related]
17. Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications. Hirawat R; Saifi MA; Godugu C Life Sci; 2021 Feb; 267():118923. PubMed ID: 33358906 [TBL] [Abstract][Full Text] [Related]
18. Immunopathogenesis and treatment of cytokine storm in COVID-19. Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477 [TBL] [Abstract][Full Text] [Related]
19. Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells. Hafezi B; Chan L; Knapp JP; Karimi N; Alizadeh K; Mehrani Y; Bridle BW; Karimi K Cells; 2021 Jul; 10(7):. PubMed ID: 34359931 [TBL] [Abstract][Full Text] [Related]
20. Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions. Root-Bernstein R Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]